Journal of Cancer Research and Therapeutics

ORIGINAL ARTICLE
Year
: 2014  |  Volume : 10  |  Issue : 4  |  Page : 951--956

Radiation therapy for clinically localized prostate cancer: Long-term results of 469 patients from a single institution in the era of dose escalation


Aparna Surapaneni1, David Schwartz1, Emmanuel Nwokedi2, Justin Rineer3, Marvin Rotman1, David Schreiber1 
1 Department of Veterans Affairs, New York Harbor Healthcare System ; Department of Radiation Oncology, SUNY Downstate Medical Center, Brooklyn, NY, USA
2 Department of Veterans Affairs, New York Harbor Healthcare System, NY, USA
3 UF Orlando Health, Orlando, Florida, USA

Correspondence Address:
David Schwartz
800, Poly Place, Suite 114A, Brooklyn, NY 11209
USA

Aims: The aim of the following study is to analyze the long-term results of veterans treated with dose escalated radiation therapy for prostate cancer. Materials and Methods: This retrospective study analyzed 469 patients who were treated between 2003 and 2010 with dose escalated radiation therapy to a minimum dose of 7560 cGy for prostate cancer at the New York Harbor Department of Veterans Affairs. Biochemical failure-free survival (bFFS) and distant metastatic-free survival (DMFS) were compared using the Kaplan-Meier method. Univariate and multivariate Cox Regression were used to measure the impact of covariates on biochemical control. Results: The median follow-up was 61 months and 95.3% of patients were followed at least 2 years. The 5-year bFFS for National Cancer Care Network low, intermediate and high risk disease were 90.3%, 86.9% and 77.3% respectively (P = 0.001). Patients with high risk disease were more likely to develop metastatic disease. The 5-year DMFS was 99.1% for low risk, 98.8% for intermediate risk and 94.5% for high-risk (P < 0.001). There were 8 prostate cancer related deaths, of which 6 had high risk disease and 2 had intermediate risk disease. The 5-year prostate cancer specific survival was 98.4%. Toxicities were generally mild, however there were two genitourinary toxicity related deaths, though in both patients there were confounding medical issues that may have contributed to their deaths. Conclusions: Dose escalated radiation in the treatment of United States Veterans appears to be well-tolerated with results in line with prior reports. Further follow-up is necessary to identify any additional late toxicities as well as to assess the durability of their biochemical control beyond 5 years.


How to cite this article:
Surapaneni A, Schwartz D, Nwokedi E, Rineer J, Rotman M, Schreiber D. Radiation therapy for clinically localized prostate cancer: Long-term results of 469 patients from a single institution in the era of dose escalation.J Can Res Ther 2014;10:951-956


How to cite this URL:
Surapaneni A, Schwartz D, Nwokedi E, Rineer J, Rotman M, Schreiber D. Radiation therapy for clinically localized prostate cancer: Long-term results of 469 patients from a single institution in the era of dose escalation. J Can Res Ther [serial online] 2014 [cited 2020 Sep 18 ];10:951-956
Available from: http://www.cancerjournal.net/article.asp?issn=0973-1482;year=2014;volume=10;issue=4;spage=951;epage=956;aulast=Surapaneni;type=0